Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: Wuhan

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Brief Description

     

     

    Product name

    Clomifene

    Synonyms

    2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine; 2-{4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine

    MOQ

    25KG

    CAS No.

    911-45-5

    Appearance

      An almost white powder

    Molecular Formula

    C26H28ClNO

    Molecular Weight

    405.9596

    Assay

    99%

    Application

    Pharma grade or research purpose

    Packing

    As per your request

    Storage

    Preserve in tight, light-resistant containers in a cool place

    Remarks

    NA

    Custom synthesis

    Available

    Supply Ability

    10000kg/month

     

    Medical use

     

    Clomifene is useful in those who are infertile due to anovulation or oligoovulation. Evidence is lacking for the use of clomifene in those who are infertile without a known reason. In such cases, studies have observed a clinical pregnancy rate 5.6% per cycle with clomifene treatment vs. 1.3%–4.2% per cycle without treatment.

     

    Clomifene has also been used with other assisted reproductive technology to increase success rates of these other modalities.

     

    Proper timing of the drug is important; it should be taken starting on about the fifth day of the cycle, and there should be frequent intercourse.

     

    The following procedures may be used to monitor induced cycles:

     

    Follicular monitoring with vaginal ultrasound, starting 4–6 days after last pill. Serial transvaginal ultrasound can reveal the size and number of developing follicles. It can also provide presumptive evidence of ovulation such as sudden collapse of the preovulatory follicle, and an increase in fluid volume in the rectouterine pouch. After ovulation, it may reveal signs of luteinization such as loss of clearly defined follicular margins and appearance of internal echoes.

    Serum estradiol levels, starting 4–6 days after last pill

    Post-coital test 1–3 days before ovulation to check whether there are at least 5 progressive sperm per HPF

    Adequacy of LH surge by urine LH surge tests 3 to 4 days after last clomifene pill

    Mid-luteal progesterone, with at least 10 ng/ml 7–9 days after ovulation being regarded as adequate.

    Repeat dosing: This 5-day treatment course can be repeated every 30 days. The dosage may be increased by 50-mg increments in subsequent cycles until ovulation is achieved. It is not recommended by the manufacturer to use clomifene for more than 6 cycles.

     

    It is no longer recommended to perform an ultrasound examination to exclude any significant residual ovarian enlargement before each new treatment cycle.

     

    Clomifene is sometimes used in the treatment of male hypogonadism as an alternative to testosterone replacement therapy. It has been found to increase testosterone levels by 2- to 2.5-fold in hypogonadal men.

     

    Clomifene has been used in the treatment of gynecomastia. It has been found to be useful in the treatment of some cases of gynecomastia but it is not as effective as tamoxifen or raloxifene for this indication. It has shown variable results for gynecomastia and hence is not recommended for treatment of the condition.

Send your message to this supplier
  • From:
  • To:
    Hanways Chempharm Co.,Limited
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service